Edwards Lifesciences Reports First Quarter Results
Edwards Lifesciences delivered strong Q1 results with sales growing 16.7% to $1.65 billion and adjusted EPS reaching $0.78. Driven by this performance, the company raised its full-year 2026 sales growth guidance to 9% to 11% and adjusted EPS guidance to $2.95 to $3.05.
Key figures
- Eps
- 0.78
- Revenue
- 1648600000
- Drug Name
- SAPIEN M3
- Guidance
- FY 2026 sales growth 9% to 11%; adjusted EPS $2.95 to $3.05
- Revenue Yoy
- 16.7%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.